Low-Energy Extracorporeal Shock Wave Therapy Ameliorates Kidney Function in Diabetic Nephropathy

Abstract EN

Background.

Diabetic nephropathy is the most common cause of end-stage renal disease.

Traditional therapy for diabetic nephropathy has focused on supportive treatment, and there is no significant effective therapy.

We investigated the effect of low-energy extracorporeal shock wave therapy on a diabetic nephropathy rat model.

Methods.

Streptozotocin-induced diabetic nephropathy rats were treated with six sessions of low-energy extracorporeal shock wave therapy (weekly for six consecutive weeks) or left untreated.

We assessed urinary creatinine and albumin, glomerular volume, renal fibrosis, podocyte number, renal inflammation, oxidative stress, and tissue repair markers (SDF-1 and VEGF) six weeks after the completion of treatment.

Results.

The six-week low-energy extracorporeal shock wave therapy regimen decreased urinary albumin excretion as well as reduced glomerular hypertrophy and renal fibrosis in the rat model of diabetic nephropathy.

Moreover, low-energy extracorporeal shock wave therapy increased podocyte number in diabetic nephropathy rats.

This was likely primarily attributed to the fact that low-energy extracorporeal shock wave therapy reduced renal inflammation and oxidative stress as well as increased tissue repair potency and cell proliferation.

Conclusions.

Low-energy extracorporeal shock wave therapy preserved kidney function in diabetic nephropathy.

Low-energy extracorporeal shock wave therapy may serve as a novel noninvasive and effective treatment of diabetic nephropathy.